120 related articles for article (PubMed ID: 38251734)
1. Disparities in the Receipt of Systemic Treatment in Metastatic Melanoma.
Kakish H; Pawar O; Bhatty M; Doh S; Mulligan KM; Rothermel LD; Bordeaux JS; Mangla A; Hoehn RS
Am J Clin Oncol; 2024 May; 47(5):239-245. PubMed ID: 38251734
[TBL] [Abstract][Full Text] [Related]
2. Association of Receipt of Systemic Treatment for Melanoma With Insurance Type in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Haynes AB; Pignone MP
Med Care; 2023 Dec; 61(12):829-835. PubMed ID: 37708348
[TBL] [Abstract][Full Text] [Related]
3. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
Haque W; Verma V; Butler EB; Teh BS
J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
[TBL] [Abstract][Full Text] [Related]
4. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
5. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
6. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
Sussman TA; Knackstedt R; Wei W; Funchain P; Gastman BR
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35998982
[TBL] [Abstract][Full Text] [Related]
8. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer.
Bagley AF; Anscher MS; Choi S; Frank SJ; Hoffman KE; Kuban DA; McGuire SE; Nguyen QN; Chapin B; Aparicio A; Pezzi TA; Smith GL; Smith BD; Hess K; Tang C
JAMA Netw Open; 2020 Mar; 3(3):e201255. PubMed ID: 32191331
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
10. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
[TBL] [Abstract][Full Text] [Related]
11. Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series.
Gaughan EM; Horton BJ
Front Oncol; 2022; 12():855782. PubMed ID: 35574303
[TBL] [Abstract][Full Text] [Related]
12. Is There an Association Between Insurance Status and Survival and Treatment of Primary Bone and Extremity Soft-tissue Sarcomas? A SEER Database Study.
Smartt AA; Jang ES; Tyler WK
Clin Orthop Relat Res; 2020 Mar; 478(3):527-536. PubMed ID: 31390340
[TBL] [Abstract][Full Text] [Related]
13. Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
Lwin TM; Kaelberer Z; Ruan M; Molina G; Boland G
Ann Surg Oncol; 2023 Aug; 30(8):5005-5012. PubMed ID: 37121988
[TBL] [Abstract][Full Text] [Related]
14. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016.
Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP
JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310
[TBL] [Abstract][Full Text] [Related]
15. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
[TBL] [Abstract][Full Text] [Related]
16. Impact of affordable care act on the treatment and outcomes for stage-IV colorectal cancer.
Jayakrishnan TT; Bakalov V; Chahine Z; Finley G; Monga D; Wegner RE
Cancer Treat Res Commun; 2020; 24():100204. PubMed ID: 32805532
[TBL] [Abstract][Full Text] [Related]
17. Mitigating disparities in breast cancer treatment at an academic safety-net hospital.
Beaulieu-Jones BR; Shewmaker G; Fefferman A; Kenzik K; Zhang T; Drake FT; Sachs TE; Hirsch AE; Merrill A; Ko NY; Cassidy MR
Breast Cancer Res Treat; 2023 Apr; 198(3):597-606. PubMed ID: 36826701
[TBL] [Abstract][Full Text] [Related]
18. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.
Amini A; Rusthoven CG; Waxweiler TV; Jones BL; Fisher CM; Karam SD; Raben D
J Am Acad Dermatol; 2016 Feb; 74(2):309-16. PubMed ID: 26670715
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Treatment Disparities: A Texas Cancer Registry Analysis of Patients with Cutaneous Melanoma.
Ramirez F; Alvarado L; Dwivedi A; Chacon J
J Immigr Minor Health; 2024 Feb; 26(1):23-33. PubMed ID: 37615821
[TBL] [Abstract][Full Text] [Related]
20. Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy.
Moon S; Pandya V; McDonald A; Basu A; Bae S; Ferguson JE
Urol Oncol; 2023 Nov; 41(11):456.e13-456.e20. PubMed ID: 37640572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
